Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.
Biosensors (Basel). 2020 Feb 14;10(2):13. doi: 10.3390/bios10020013.
Lysophosphatidic acid (LPA) is present during the medical condition of ovarian cancer at all stages of the disease, and, therefore possesses considerable potential as a biomarker for screening its presence in female patients. Unfortunately, there is currently no assay for this biomarker. In the present work, we introduce a test based on the duel protein system of actin and gelsolin that could allow the quantitative measurement of LPA in serum samples in a biosensing format. In order to evaluate this possibility, actin protein was dye-modified and complexed with gelsolin protein, followed by surface deposition onto silica nanoparticles. This solid-phase system was exposed to serum samples containing various concentrations of LPA and analyzed by fluorescence microscopy. Measurements conducted for the LPA-containing serum samples were higher after exposure to the developed test than samples without LPA. Early results suggest a limit of detection of 5 μM LPA in serum. The eventual goal is to employ the chemistry described here in a biosensor configuration for the large population-scale, rapid screening of women for the potential occurrence of ovarian cancer.
溶血磷脂酸（LPA）存在于卵巢癌的各个阶段的疾病状态中，因此具有作为女性患者筛查其存在的生物标志物的巨大潜力。不幸的是，目前没有针对该生物标志物的检测方法。在本工作中，我们引入了一种基于肌动蛋白和凝胶蛋白双蛋白系统的测试，可以允许在生物传感格式中定量测量血清样品中的 LPA。为了评估这种可能性，肌动蛋白蛋白被染料修饰并与凝胶蛋白复合，然后沉淀到硅纳米颗粒上。将这个固相系统暴露于含有不同浓度 LPA 的血清样品中，并通过荧光显微镜进行分析。在暴露于开发的测试后，含 LPA 的血清样品的测量值高于不含 LPA 的样品。初步结果表明血清中 LPA 的检测限为 5 μM。最终目标是将这里描述的化学方法应用于生物传感器配置中，用于大规模快速筛选女性是否存在卵巢癌的潜在发生。
